In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

3rd Annual Gene Therapy for Blood Disorders

Mar 29, 2022 - 08:50 AM - Mar 31, 05:40 PM
Hanson Wade
Hilton Boston Logan Airport, One Hotel Drive,

ZIP: 02128
Phone: + 1 415-735-3289

Ticket Price: USD 2599.00 - USD 4397.00

In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field, enabling you to progress your pipeline to address the significant unmet need in this field.

Focused specifically on hemophilia, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches, this event is an invaluable opportunity to learn the realities of durability challenges, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field.

Incorporating insights from translational, clinical and commercial industry experts, as well as leading clinicians actively involved in late-stage trials, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption.

Tickets    https://go.evvnt.com/947702-1?pid=1052
Brochure https://go.evvnt.com/947702-2?pid=1052

Conference Only - Industry Rate - Physical Attendance USD 2999.00
Conference + 1 Workshop - Industry Rate - Physical Attendance USD 3698.00
Conference + 2 Workshops - Industry Rate - Physical Attendance USD 4397.00
Conference Only - Academic Rate - Physical Attendance USD 2599.00
Conference + 1 Workshop - Academic Rate - Physical Attendance USD 3198.00
Conference + 2 Workshops - Academic Rate - Physical Attendance USD 3797.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Speaker Details

Gabriella Denning, VP Research & Development, Expression Therapeutics, Guy Young, Director Hemostasis & Thrombosis Center, Children’s Hospital LA, Ian Winburn, Global Medical Lead Haemophilia, Pfizer, Wendy Pang, VP Research & Translational Medicine, Jasper Tx, Brian OMahoney, CEO, Irish Haemophilia Society, Clark Paramore, Head of Value Demonstration & HEOR, bluebird bio, Dawn Henke, Director, Standards Coordinating Body, Mark Trusheim, Strategic Director, NEWDIGS MIT, Adam Wufsus, Medical Director Rare Blood Disorders, Novo Nordisk, Antti Kourula, Global Vice President Commercial President, CSL Behring, Jonathan Schwarts, Chief Medical Officer, Rocket Pharmaceuticals, Lesha Shah, Co-Chair, Pediatric Gene Therapy & Medical Ethics Working Group, Glenn Mones, Advocacy Leader, The Coalition Haemophilia B, Karen Pinachyan, Head of Medical Affairs Europe, CSL Behring, Meagan O’Brien, Senior Medical Director, Regeneron, Oscar Segurado, Chief Medical Officer, ASC Therapeutics, David Wilcox, VP Research & Translational Medicine, Medical College of Wisconsin, Graham Foster, Professor of Hepatology, Queen Mary University of London, Rahul Palchaudhuri, Director of Biotherapeutics, Magenta Therapeutics

Event Categories
Keywords: conference


Events Calendar

27 28 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2


VIP Life Time Subscription to our Newsletters!